WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its ADC technology, today reported financial results for the three-month period ended September 30, 2015 – the first quarter of the Company’s 2016 fiscal year. ImmunoGen also provided an update on product programs and reiterated its guidance for its 2016 fiscal year.
“We believe mirvetuximab soravtansine has the potential to make an important difference for many patients with FRa-positive cancers and look forward to the upcoming data presentations at AACR-NCI-EORTC,” commented Daniel Junius, President and CEO. “Of particular note are the findings suggesting that the level of FRa expression on patient tumors has a marked impact on response to mirvetuximab soravtansine. As noted in the abstract that became public yesterday, the response rate was 53% for the patients reported at ASCO and 80% in the subset with the highest expression – about half of the 22 patients treated. Updated response data, including duration, for these patients will be reported at AACR-NCI-EORTC.”
Help employers find you! Check out all the jobs and post your resume.
